Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
26.7M
-
Shares change
-
+1.95M
-
Total reported value, excl. options
-
$612M
-
Value change
-
+$44.7M
-
Put/Call ratio
-
0.71
-
Number of buys
-
49
-
Number of sells
-
-33
-
Price
-
$22.95
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q3 2018
140 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q3 2018.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.7M shares
of 27.8M outstanding shares and own 96% of the company stock.
Largest 10 shareholders include ORACLE INVESTMENT MANAGEMENT INC (4.19M shares), CREDIT SUISSE AG/ (3.65M shares), Birchview Capital, LP (2.18M shares), BlackRock Inc. (1.79M shares), Vanguard Group Inc (1.29M shares), CANNELL PETER B & CO INC (1.12M shares), BLAIR WILLIAM & CO/IL (879K shares), AMUNDI PIONEER ASSET MANAGEMENT INC (745K shares), ArrowMark Colorado Holdings LLC (695K shares), and Chicago Capital, LLC (630K shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.